Related Experiment Video
Updated: Jun 19, 2025

A Mouse Model to Investigate the Role of Cancer-Associated Fibroblasts in Tumor Growth
Published on: December 22, 2020
Fibroblasts Promote Resistance to KRAS Silencing in Colorectal Cancer Cells
Susana Mendonça Oliveira1,2,3,4, Patrícia Dias Carvalho1,2,5, André Serra-Roma1,2
1i3S-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Rua Alfredo Allen 208, 4200-135 Porto, Portugal.
Abstract:
Colorectal cancer (CRC) responses to KRAS-targeted inhibition have been limited due to low response rates, the mechanisms of which remain unknown. Herein, we explored the cancer-associated fibroblasts (CAFs) secretome as a mediator of resistance to KRAS silencing. CRC cell lines HCT15, HCT116, and SW480 were cultured either in recommended media or in conditioned media from a normal colon fibroblast cell line (CCD-18Co) activated with rhTGF-β1 to induce a CAF-like phenotype. The expression of membrane stem cell markers was analyzed by flow cytometry. Stem cell potential was evaluated by a sphere formation assay. RNAseq was performed in KRAS-silenced HCT116 colonospheres treated with either control media or conditioned media from CAFs. Our results demonstrated that KRAS-silencing up-regulated CD24 and down-regulated CD49f and CD104 in the three cell lines, leading to a reduction in sphere-forming efficiency. However, CAF-secreted factors restored stem cell marker expression and increased stemness. RNA sequencing showed that CAF-secreted factors up-regulated genes associated with pro-tumorigenic pathways in KRAS-silenced cells, including KRAS, TGFβ, NOTCH, WNT, MYC, cell cycle progression and exit from quiescence, epithelial-mesenchymal transition, and immune regulation. Overall, our results suggest that resistance to KRAS-targeted inhibition might derive not only from cell-intrinsic causes but also from external elements, such as fibroblast-secreted factors.
Insights
Cancer-associated fibroblasts (CAFs) can drive resistance to KRAS-targeted therapy in colorectal cancer (CRC). CAF secretomes restore cancer stem cell markers and promote tumor-promoting pathways, suggesting external factors contribute to treatment failure.
Area of Science:
- Oncology
- Cancer Biology
- Molecular Targeted Therapy
Background:
- Colorectal cancer (CRC) exhibits limited response to KRAS-targeted therapies.
- Mechanisms underlying resistance to KRAS inhibition in CRC are not fully understood.
Purpose of the Study:
- To investigate the role of cancer-associated fibroblasts (CAFs) secretome in mediating resistance to KRAS silencing in CRC.
- To explore how CAF-secreted factors influence cancer stem cell properties and signaling pathways in KRAS-silenced CRC cells.
Main Methods:
- CRC cell lines (HCT15, HCT116, SW480) were cultured in normal or CAF-conditioned media.
- Flow cytometry analyzed stem cell marker expression (CD24, CD49f, CD104).
- Sphere formation assays assessed stem cell potential.
- RNA sequencing (RNAseq) analyzed gene expression in KRAS-silenced cells treated with CAF-conditioned media.
Main Results:
- KRAS silencing reduced stem cell marker expression and sphere-forming efficiency.
- CAF-secreted factors reversed these effects, restoring stem cell markers and increasing stemness.
- RNAseq revealed CAF factors up-regulated pro-tumorigenic pathways (KRAS, TGFβ, NOTCH, WNT, MYC, EMT) in KRAS-silenced cells.
Conclusions:
- Resistance to KRAS-targeted inhibition in CRC may involve both cell-intrinsic factors and external signals from the tumor microenvironment, specifically CAF secretomes.
- Fibroblast-secreted factors can promote stemness and activate oncogenic pathways, contributing to therapeutic resistance.
More Related Videos
09:16Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes
Published on: June 3, 2018
10:13A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells
Published on: July 3, 2013
Related Concept Videos
Introduction to Fibroblasts
Treatment Resistant Cancers
The Ras Gene
Ras is a...